The Pancreatic Ductal Adenocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic Ductal Adenocarcinoma Market.

Some of the key takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Pancreatic Ductal Adenocarcinoma treatment therapies with a considerable amount of success over the years. 
• Pancreatic Ductal Adenocarcinoma companies working in the treatment market are Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, and others, are developing therapies for the Pancreatic Ductal Adenocarcinoma treatment 

• Emerging Pancreatic Ductal Adenocarcinoma therapies in the different phases of clinical trials are- DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, and others are expected to have a significant impact on the Pancreatic Ductal Adenocarcinoma market in the coming years.  
• In November 2023, CG Pharmaceuticals has initiated a Phase II clinical trial of ivaltinostat, utilizing the recommended Phase II dose (RP2D), for addressing metastatic pancreatic ductal adenocarcinoma (PDAC).
• In January 2022, Jiangsu Alphamab Biopharmaceuticals initiated a multicenter, randomized, double-blind Phase III study in first-line Advanced Pancreatic Ductal Adenocarcinoma subjects (ENREACH-PDAC-01) to compare the efficacy and safety of KN046 combined with Gemcitabine and Nab-Paclitaxel versus placebo combined with Gemcitabine and Nab-Paclitaxel.
• In July 2022, Cend Therapeutics, Inc. reported that data from the Phase 1b study of CEND-1, Cend’s lead investigational drug, in combination with gemcitabine and nab-paclitaxel for the treatment of first-line, metastatic pancreatic ductal adenocarcinoma (“mPDAC”) were published in The Lancet Gastroenterology and Hepatology.
• In July 2022, I-Mab reported that a Phase 1 international multi-center clinical trial (IMCT) for patients with solid tumors, such as gastric cancer, gastroesophageal junction carcinoma, esophageal adenocarcinoma, and pancreatic ductal carcinoma, has treated the first patient in China with TJ-CD4B (also known as ABL111), a novel Claudin 18.2 x 4-1BB bispecific antibody.
• In June 2022, The mRNA-based personalized neoantigen-specific immunotherapy (iNeST) autogene cevumeran (also known as BNT122, RO7198457) in combination with the anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC) was recently evaluated for safety and tolerability in a first-in-human Phase 1 study. It was confirmed that the method of tumor profiling for tailored vaccine creation and on-demand production of iNeST in a clinically appropriate period is feasible. The early findings revealed a good safety profile and heartening hints of clinical activity.
• In June 2022, In order to advance Motixafortide through a randomized Phase 2b clinical trial in pancreatic ductal adenocarcinoma, or PDAC, BioLineRx Ltd. stated that the firm had entered into a collaboration agreement with GenFleet Therapeutics, an immuno-oncology-focused biopharmaceutical firm with headquarters in China.
• In May 2022, Elicio Therapeutics announced that it had signed a clinical supply agreement with Regeneron to test the safety and effectiveness of using Regeneron’s Libtayo® (cemiplimab), a fully human monoclonal antibody that targets the immune checkpoint receptor PD-1 on T cells, in combination with Elicio’s lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in patients with KRAS-driven tumors. Stage III and Stage IV non-small cell lung cancer (NSCLC), Stage IV colorectal cancer (CRC), and unresectable, locally progressed, or oligometastatic pancreatic ductal adenocarcinoma (PDAC) are among the KRAS-driven malignancies that will be examined with the combo therapy
• In May 2022, The Phase 2 phase of Purple Biotech Ltd.’s ongoing investigation of CM24, a first-in-class monoclonal antibody with the potential to treat various malignancies, has begun. The objective of the open-label, multicenter Phase 2 research is to assess the safety and tolerability of CM24 in combination with the PD-1 inhibitor Opdivo® (nivolumab) and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC). Evaluating preliminary efficacy in PDAC treated as a second line is the study’s main goal.
• In March 2022, The company’s flagship asset, mitazalimab, is being tested in the ongoing OPTIMIZE-1 clinical Phase Ib/II trial for the treatment of first-line metastatic pancreatic cancer. Phase Ib of the research has been successfully finished with the safety assessment of the second dose-escalation cohort (900 g/kg of mitazalimab in conjunction with mFOLFIRINOX) being completed. The 900 g/kg mitazalimab dose had been deemed safe by the Data Review Committee, and it was suggested that the Phase II study should proceed with the current dosing level. Phase II enrollment has started and is still going on at locations in Europe. Patients with metastatic pancreatic ductal adenocarcinoma are being evaluated for the safety and effectiveness of mitazalimab in OPTIMIZE-1, an open-label, multi-center Phase Ib/II research.

Pancreatic Ductal Adenocarcinoma Overview

Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer that originates in the cells lining the pancreatic ducts, which are the tubes that carry digestive enzymes from the pancreas to the small intestine. PDAC is the most common type of pancreatic cancer, accounting for about 85% of cases. It is often diagnosed at an advanced stage and has a poor prognosis.

Get a Free Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight

Emerging Pancreatic Ductal Adenocarcinoma Drugs Under Different Phases of Clinical Development Include:

• DCC-3116: Deciphera Pharmaceuticals
• RMC-6236: Revolution Medicines
• SX-682: Syntrix Biosystems
• AMP 945: Amplia Therapeutics
• ZB131: ZielBio
• CEND-1: Cend Therapeutics Inc
• Onvansertib: Cardiff Oncology
• YH003: Eucure Biopharma
• KN046: Jiangsu Alphamab Biopharmaceuticals

Pancreatic Ductal Adenocarcinoma Route of Administration

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous

Pancreatic Ductal Adenocarcinoma Molecule Type

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types, such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment

• Pancreatic Ductal Adenocarcinoma Assessment by Product Type
• Pancreatic Ductal Adenocarcinoma By Stage and Product Type
• Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
• Pancreatic Ductal Adenocarcinoma By Stage and Route of Administration
• Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
• Pancreatic Ductal Adenocarcinoma by Stage and Molecule Type

DelveInsight’s Pancreatic Ductal Adenocarcinoma Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Pancreatic Ductal Adenocarcinoma product details are provided in the report. Download the Pancreatic Ductal Adenocarcinoma pipeline report to learn more about the emerging Pancreatic Ductal Adenocarcinoma therapies

Some of the key companies in the Pancreatic Ductal Adenocarcinoma Therapeutics Market include:

Key companies developing therapies for Pancreatic Ductal Adenocarcinoma are – Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.

Pancreatic Ductal Adenocarcinoma Pipeline Analysis:

The Pancreatic Ductal Adenocarcinoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Ductal Adenocarcinoma Treatment.
• Pancreatic Ductal Adenocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pancreatic Ductal Adenocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Ductal Adenocarcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma drugs and therapies

Pancreatic Ductal Adenocarcinoma Pipeline Market Drivers

• Increasing pervasiveness of the disease, increasing demand of targeted therapy are some of the important factors that are fueling the Pancreatic Ductal Adenocarcinoma Market.

Pancreatic Ductal Adenocarcinoma Pipeline Market Barriers

• However, lack of early diagnostic markers, complicated and multifactorial nature of disease, diverse genetics and rapid metastasis and other factors are creating obstacles in the Pancreatic Ductal Adenocarcinoma Market growth.

Scope of Pancreatic Ductal Adenocarcinoma Pipeline Drug Insight    

• Coverage: Global
• Key Pancreatic Ductal Adenocarcinoma Companies: Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, and others
• Key Pancreatic Ductal Adenocarcinoma Therapies: DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, and others
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment: Pancreatic Ductal Adenocarcinoma current marketed and Pancreatic Ductal Adenocarcinoma emerging therapies
• Pancreatic Ductal Adenocarcinoma Market Dynamics: Pancreatic Ductal Adenocarcinoma market drivers and Pancreatic Ductal Adenocarcinoma market barriers 

Request for Sample PDF Report for Pancreatic Ductal Adenocarcinoma Pipeline Assessment and clinical trials

Table of Contents

1. Pancreatic Ductal Adenocarcinoma Report Introduction

2. Pancreatic Ductal Adenocarcinoma Executive Summary

3. Pancreatic Ductal Adenocarcinoma Overview

4. Pancreatic Ductal Adenocarcinoma- Analytical Perspective In-depth Commercial Assessment

5. Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics

6. Pancreatic Ductal Adenocarcinoma Late Stage Products (Phase II/III)

7. Pancreatic Ductal Adenocarcinoma Mid Stage Products (Phase II)

8. Pancreatic Ductal Adenocarcinoma Early Stage Products (Phase I)

9. Pancreatic Ductal Adenocarcinoma Preclinical Stage Products

10. Pancreatic Ductal Adenocarcinoma Therapeutics Assessment

11. Pancreatic Ductal Adenocarcinoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pancreatic Ductal Adenocarcinoma Key Companies

14. Pancreatic Ductal Adenocarcinoma Key Products

15. Pancreatic Ductal Adenocarcinoma Unmet Needs

16 . Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers

17. Pancreatic Ductal Adenocarcinoma Future Perspectives and Conclusion

18. Pancreatic Ductal Adenocarcinoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/